Breath Test for Diagnosing Fungal Pneumonia
This type of fungal pneumonia is difficult to diagnose and in most cases a lung biopsy is necessary to obtain more accurate identification. However, such an invasive procedure could be difficult, and even dangerous, for debilitated patients with weakened immune systems, including organ or bone marrow transplant recipients and patients on chemotherapy.
Hence, the challenge for experts is to find a noninvasive method that can also identify the type of fungus causing pneumonia to enable timely and targeted treatment in these cases. Sophia Koo, MD, of Brigham and Women's Hospital in Boston (MA, USA), and her colleagues set out to find a unique "chemical signature" in the breath of patients being evaluated for fungal pneumonia. They prospectively collected breath samples from patients with suspected invasive fungal pneumonia from 2011 to 2013.
In their research, Dr. Koo et al. identified several compounds, or metabolites, normally produced by Aspergillus fumigatus and other fungi that can cause pneumonia. The next step was to analyse breath samples from 64 patients with suspected cases of invasive aspergillosis. This would allow the team to assess if it was possible to distinguish patients with this fungal pneumonia from patients who did not have this illness.
New Technique Detects Fungal Infection with High Accuracy
Based on the identification of these fungal compounds in the breath samples, the researchers were able to identify patients with the fungal infection with high accuracy: 94 percent sensitivity and 93 percent specificity. This means that the "breath test" was able to detect 94 percent of patients who actually had or probably had the disease, and misidentified as infected seven percent of patients who did not have the infection.
According to the hospital team, the breath collection procedure was implemented without any problem. It was well-tolerated, including by patients who had difficulty breathing or required supplemental oxygen.
"Identification of the underlying microbial etiology remains elusive in most patients with pneumonia, even with invasive diagnostic measures," Dr. Koo noted. "Our findings provide proof-of-concept that we can harness detection of species-specific metabolites to identify the precise microbial cause of pneumonia, which may guide appropriate treatment of these infections."
More work is needed to validate the findings and refine the approach before it can be considered for clinical use, the researchers said. If supported by future research, the new technique also may be used in other types of pneumonia. "We can likely also use this volatile metabolite profiling approach to identify other, more common causes of pneumonia," Dr. Koo pointed out.
Image Credit: Wikimedia Commons
Published on : Fri, 24 Oct 2014
Print as PDF
The technical and clinical reference standard for all B·R·A·H·M·S PCT assays. All clinical cut-offs and algorithms were developed based on B·R·A·H·M·S PCT sensitive KRYPTOR. Homogeneous immunoassay for the quantitative d
Monitor vital signs of sensitive patients with reliable, smart and intuitive technology Not available in the US Sensitive patients, like neonates, require comfortable care. With transcutaneous monitoring, you can easily keep track of the oxygenation...
17 critical parameters from a blood sample as small as 45 µL Not available in the US When the sample is small but your diagnostic needs are big, the ABL90 FLEX PLUS blood gas analyzer provides critical insights with a turnaround time of less than...
The fully featured ICU ventilator, HAMILTON-MR1, guarantees uncompromised continuous ventilation care from the ICU to the MRI scanner and back. Its reliability and high performance, with advanced lung-protective strategies and patient-adaptive modes,...
NovaPort cannulas: The safe access to the vascular system. NovaPort® twin double lumen cannulas are specifically developed for veno-venous vascular access. NovaPort one single lumen cannulas are specifically developed for the percutaneous connection (KU)...